A TRAIL-TL1A Paracrine Network Involving Adipocytes, Macrophages, and Lymphocytes Induces Adipose Tissue Dysfunction Downstream of E2F1 in Human Obesity

Elevated expression of E2F1 in adipocyte fraction of human visceral adipose tissue (hVAT) associates with a poor cardiometabolic profile. We hypothesized that beyond directly activating autophagy and MAP3K5 (ASK)–MAP kinase signaling, E2F1 governs a distinct transcriptome that contributes to adipose tissue and metabolic dysfunction in obesity. We performed RNA sequencing of hVAT samples from age-, sex-, and BMI-matched patients, all obese, whose visceral E2F1 protein expression was either high (E2F1high) or low (E2F1low). Tumor necrosis factor superfamily (TNFSF) members, including TRAIL (TNFSF10), TL1A (TNFSF15), and their receptors, were enriched in E2F1high. While TRAIL was equally expressed in adipocytes and stromal vascular fraction (SVF), TL1A was mainly expressed in SVF, and TRAIL-induced TL1A was attributed to CD4+ and CD8+ subclasses of hVAT T cells. In human adipocytes, TL1A enhanced basal and impaired insulin-inhibitable lipolysis and altered adipokine secretion, and in human macrophages it induced foam cell biogenesis and M1 polarization. Two independent human cohorts confirmed associations between TL1A and TRAIL expression in hVAT and higher leptin and IL6 serum concentrations, diabetes status, and hVAT-macrophage lipid content. Jointly, we propose an intra-adipose tissue E2F1-associated TNFSF paracrine loop engaging lymphocytes, macrophages, and adipocytes, ultimately contributing to adipose tissue dysfunction in obesity.

[1]  B. Spiegelman,et al.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.

[2]  Jun Zhang,et al.  TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. , 2002, Immunity.

[3]  J. Auwerx,et al.  E2Fs regulate adipocyte differentiation. , 2002, Developmental cell.

[4]  P. Wei,et al.  Expression, Localization, and Functional Activity of TL1A, a Novel Th1-Polarizing Cytokine in Inflammatory Bowel Disease 1 , 2003, The Journal of Immunology.

[5]  J. Auwerx,et al.  Impaired pancreatic growth, β cell mass, and β cell function in E2F1 –/– mice , 2004 .

[6]  J. Auwerx,et al.  Impaired pancreatic growth, beta cell mass, and beta cell function in E2F1 (-/- )mice. , 2004, The Journal of clinical investigation.

[7]  C. Harris,et al.  Chronic inflammation promotes retinoblastoma protein hyperphosphorylation and E2F1 activation. , 2005, Cancer research.

[8]  A. Lackner,et al.  Intestinal double‐positive CD4+CD8+ T cells are highly activated memory cells with an increased capacity to produce cytokines , 2006, European journal of immunology.

[9]  A. Saltiel,et al.  Obesity induces a phenotypic switch in adipose tissue macrophage polarization. , 2007, The Journal of clinical investigation.

[10]  Michael Q. Zhang,et al.  Regulation of the PDK4 Isozyme by the Rb-E2F1 Complex* , 2008, Journal of Biological Chemistry.

[11]  E. Podack,et al.  Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation , 2008, The Journal of experimental medicine.

[12]  P. Sfikakis,et al.  Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. , 2008, Clinical immunology.

[13]  C. Sardet,et al.  The CDK4–pRB–E2F1 pathway controls insulin secretion , 2009, Nature Cell Biology.

[14]  G. Wilkinson,et al.  The TNF-Like Protein 1A–Death Receptor 3 Pathway Promotes Macrophage Foam Cell Formation In Vitro , 2010, The Journal of Immunology.

[15]  A. Chervonsky,et al.  Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in mice. , 2010, The Journal of clinical investigation.

[16]  T. Ślebioda,et al.  Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia , 2011, Mucosal Immunology.

[17]  Bent Stamnes.  Elevated , 2011, SIGGRAPH '11.

[18]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[19]  Johan Auwerx,et al.  E2F transcription factor-1 regulates oxidative metabolism , 2011, Nature Cell Biology.

[20]  Merlin C. Thomas,et al.  TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. , 2012, Clinical science.

[21]  S. Fried,et al.  Glucocorticoids antagonize tumor necrosis factor-α-stimulated lipolysis and resistance to the antilipolytic effect of insulin in human adipocytes. , 2012, American journal of physiology. Endocrinology and metabolism.

[22]  D. Chisholm,et al.  Insulin-sensitive obesity in humans – a ‘favorable fat’ phenotype? , 2012, Trends in Endocrinology & Metabolism.

[23]  P. Sfikakis,et al.  Increased levels of soluble TNF-like cytokine 1A in ankylosing spondylitis. , 2013, Rheumatology.

[24]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[25]  M. Morris,et al.  On the TRAIL of obesity and diabetes , 2013, Trends in Endocrinology & Metabolism.

[26]  H. Shapiro,et al.  Adipose tissue foam cells are present in human obesity. , 2013, The Journal of clinical endocrinology and metabolism.

[27]  P. Fischer-Posovszky,et al.  TRAIL (TNF-related apoptosis-inducing ligand) regulates adipocyte metabolism by caspase-mediated cleavage of PPARgamma , 2013, Cell Death and Disease.

[28]  F. Jiang,et al.  TRAIL/DR5 Signaling Promotes Macrophage Foam Cell Formation by Modulating Scavenger Receptor Expression , 2014, PloS one.

[29]  M. Fasshauer,et al.  Fas and FasL expression in human adipose tissue is related to obesity, insulin resistance, and type 2 diabetes. , 2014, The Journal of clinical endocrinology and metabolism.

[30]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[31]  Juan Shi,et al.  RIP1 modulates death receptor mediated apoptosis and autophagy in macrophages , 2015, Molecular oncology.

[32]  Min Liu,et al.  Tumor necrosis factor–related apoptosis-inducing ligand induces the expression of proinflammatory cytokines in macrophages and re-educates tumor-associated macrophages to an antitumor phenotype , 2015, Molecular biology of the cell.

[33]  Arianne C. Richard,et al.  The TNF‐family cytokine TL1A: from lymphocyte costimulator to disease co‐conspirator , 2015, Journal of leukocyte biology.

[34]  P. Fischer-Posovszky,et al.  TNF‐related apoptosis‐inducing ligand promotes human preadipocyte proliferation via ERK1/2 activation , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  I. Harman-boehm,et al.  Elevated autophagy gene expression in adipose tissue of obese humans: A potential non-cell-cycle-dependent function of E2F1 , 2015, Autophagy.

[36]  R. Wallace,et al.  The beneficial pleiotropic effects of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) within the vasculature: A review of the evidence. , 2016, Atherosclerosis.

[37]  F. Pattou,et al.  E2F1 mediates sustained lipogenesis and contributes to hepatic steatosis. , 2016, The Journal of clinical investigation.

[38]  D. Allison,et al.  Regarding Obesity as a Disease: Evolving Policies and Their Implications. , 2016, Endocrinology and metabolism clinics of North America.

[39]  A. Rudich,et al.  Transcriptional Dysregulation of Adipose Tissue Autophagy in Obesity. , 2016, Physiology.

[40]  P. Fischer-Posovszky,et al.  TRAIL (TNF-related apoptosis-inducing ligand) inhibits human adipocyte differentiation via caspase-mediated downregulation of adipogenic transcription factors , 2016, Cell Death and Disease.

[41]  P. Fischer-Posovszky,et al.  Trail (TNF-related apoptosis-inducing ligand) induces an inflammatory response in human adipocytes , 2017, Scientific Reports.

[42]  H. Walczak,et al.  Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy , 2017, Nature Reviews Cancer.

[43]  Xiaopan Chen,et al.  Whole-genome expression analyses of type 2 diabetes in human skin reveal altered immune function and burden of infection , 2017, Oncotarget.

[44]  I. Harman-boehm,et al.  ASK1 (MAP3K5) is transcriptionally upregulated by E2F1 in adipose tissue in obesity, molecularly defining a human dys-metabolic obese phenotype , 2017, Molecular metabolism.

[45]  A. Rudich,et al.  Adipose tissue conditioned media support macrophage lipid-droplet biogenesis by interfering with autophagic flux. , 2017, Biochimica et biophysica acta. Molecular and cell biology of lipids.

[46]  K. Clément,et al.  The FAT Score, a Fibrosis Score of Adipose Tissue: Predicting Weight-Loss Outcome After Gastric Bypass , 2017, The Journal of clinical endocrinology and metabolism.

[47]  F. Pattou,et al.  E2F1 promotes hepatic gluconeogenesis and contributes to hyperglycemia during diabetes , 2018, Molecular metabolism.

[48]  Michal Gordon,et al.  NeatSeq-Flow: A Lightweight High-Throughput Sequencing Workflow Platform for Non-Programmers and Programmers Alike , 2018, bioRxiv.

[49]  P. Vandenabeele,et al.  TL1A regulates adipose-resident innate lymphoid immune responses and enables diet-induced obesity in mice , 2020, International Journal of Obesity.

[50]  J. Després,et al.  Obesity Phenotypes, Diabetes, and Cardiovascular Diseases. , 2020, Circulation research.